Socioeconomic differences in mortality amenable to health care among Finnish adults 1992-2003: 12 year follow up using individual level linked population register data

Alison K McCallum1*, Kristiina Manderbacka2, Martti Arffman2, Alastair H Leyland3 and Ilmo Keskimäki2,4

Abstract

Background: Finland decentralised its universal healthcare system and introduced market reforms in the 1990s. Despite a commitment to equity, previous studies have identified persistent socio-economic inequities in healthcare, with patterns of service use that are more pro-rich than in most other European countries. To examine whether similar socio-economic patterning existed for mortality amenable to intervention in primary or specialist care, we investigated trends in amenable mortality by income group from 1992-2003.

Methods: We analysed trends in all cause, total disease and mortality amenable to health care using individual level data from the National Causes of Death Register for those aged 25 to 74 years in 1992-2003. These data were linked to sociodemographic data for 1990-2002 from population registers using unique personal identifiers. We examined trends in causes of death amenable to intervention in primary or specialist healthcare by income quintiles.

Results: Between 1992 and 2003, amenable mortality fell from 93 to 64 per 100,000 in men and 74 to 54 per 100,000 in women, an average annual decrease in amenable mortality of 3.6% and 3.1% respectively. Over this period, all cause mortality declined less, by 2.8% in men and 2.5% in women. By 2002-2003, amenable mortality among men in the highest income group had halved, but the socioeconomic gradient had increased as amenable mortality reduced at a significantly slower rate for men and women in the lowest income quintile. Compared to men and women in the highest income quintile, the risk ratio for mortality amenable to primary care had increased to 14.0 and 20.5 respectively, and to 8.8 and 9.36 for mortality amenable to specialist care.

Conclusions: Our findings demonstrate an increasing socioeconomic gradient in mortality amenable to intervention in primary and specialist care. This is consistent with the existing evidence of inequity in healthcare use in Finland and provides supporting evidence of changes in the socioeconomic gradient in health service use and in important outcomes. The potential adverse effect of healthcare reform on timely access to effective care for people on low incomes provides a plausible explanation that deserves further attention.

Keywords: Socioeconomic factors, Avoidable deaths, Equity in health care, Registers, Record linkage, Finland

* Correspondence: alison.mccallum@nhslothian.scot.nhs.uk
1Directorate of Public Health and Health Policy, NHS Lothian, Waverley Gate, 2-4 Waterloo Place, Edinburgh EH1 3EG, Scotland
Full list of author information is available at the end of the article

© 2013 McCallum et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background
Over the past fifty years, improved living conditions and comprehensive health services have reduced rates of premature death [1-3]. One aspect of health system performance is the variation in amenable mortality, premature deaths that should be avoided by timely and effective health service intervention [4]. Lists of causes of amenable mortality have been refined over time to reflect increased availability of effective interventions and the impact of health system factors on outcomes. To understand better the relationship between healthcare and amenable mortality, studies have tried to distinguish between mortality amenable to prevention, for example, immunisation, chronic disease management delivered largely in primary care, and interventions undertaken by specialist services [5-7].

Nolte and McKee found that Finland had higher amenable mortality rates than many comparable countries with only Ireland, United Kingdom and Portugal having higher rates [1]. Between 1997-8 and 2003-3 the rate fell by more than 20%. In Finland there is evidence of widespread socio-economic differences in use of services [8-10] quality of care [9,11,12] and outcomes [11,13,14]. Equity in health care and reducing premature death from amenable causes are important objectives of health policy for all countries. Few studies, however, have examined changes in amenable mortality over time by socioeconomic status [15-17] or education [18] by type or place of intervention. Since socioeconomic inequities in access to and provision of services remain problematic, this is a significant gap in the literature.

As socio-economic differences in amenable mortality are a potential consequence of the inverse care law [19], an understanding of the context in which prevention and treatment is delivered is important. In Finland, a comprehensive healthcare system based on a network of primary healthcare centres linked to municipalities was established in 1972 [20]. The recession of the 1990s halted the expansion in primary care and preventive services [21,22] a market in the provision of primary care developed and private sector specialist ambulatory care services expanded. These services were available primarily to those in regular employment, with others reliant on municipal health centres. The recession also coincided with devolution of health service strategy to municipalities and, while there were attempts to introduce markets and commissioning with tight control over activity and budgets [23], most municipalities had limited influence over the increasing costs in specialist care. While many countries have adopted similar reforms, the Finnish experience is important for three reasons.

1) Socio-economic inequities in access to care [8,24,25] appear greater in Finland than in many other high income countries

2) Despite structural and health service changes, Finland retained substantial social welfare programmes. While income inequalities rose between 1992 and 2004 [23], they remained lower than in the United Kingdom or Sweden.

3) Welfare interventions, such as help with housing and daily living costs, reduced the potential for changes in access to social care to affect premature mortality, particularly causes amenable to primary care, despite the reduction in the income share received by those with the lowest incomes. [26].

This study analyses changes in the socioeconomic distribution of mortality amenable to primary prevention, early detection and improved treatment and medical care between 1992 and 2003 in Finland. During this period of economic recession, subsequent boom, and structural change in Finland, health service expenditure declined then slowly recovered, hospital productivity increased and patient co-payments rose [21]. Based on existing evidence of inequities in the access to and provision of services, mortality from specific causes amenable to health care and the changes in the Finnish health care system over the study period, we hypothesised that amenable mortality would be patterned by income. We also aimed to examine how the balance between mortality amenable to prevention, early intervention and treatment, and improved treatment and medical care in primary and specialist settings would change over time.

Methods
Classification of causes of death
Statistics Finland extracted individual data from the causes of death register for all deaths in the Finnish population aged 25-74 years between 1992 and 2003. The resident population aged 25-74 years formed the population at risk. The period studied covered the transition from ICD9 to ICD10 in 1996. Statistics Finland developed and validated procedures for forward and back translation. The completeness of death registration, the process for expert review of disputed cases and the high autopsy rate for deaths from suspicious and external causes together provide high quality mortality data [27].

Classification of amenable mortality
We classified deaths amenable to health care based on the Nolte and McKee list [1,2]. We included premature death from chronic obstructive pulmonary disease (COPD); a category that includes chronic bronchitis and emphysema. In Finland, premature deaths classified as being primarily due to COPD are rare. Inclusion of this category reflects work undertaken by researchers in New Zealand, supported by an international expert reference group [28]. This reflects recognition that, while COPD is
largely preventable by being a non-smoker, effective interventions available in primary care include active chronic disease management: prevention of exacerbations through smoking cessation and immunization against influenza and pneumococcal disease, rapid treatment and pulmonary rehabilitation. We analysed deaths from ischaemic heart disease separately. To take account of the small number of deaths from individual conditions, we grouped them by whether they were mainly amenable to individual preventive services, early detection and intervention, and improved treatment and medical care [5]. We further subdivided the improved treatment and medical care group into whether treatment was undertaken mostly in primary or specialist care [2,29,30] (see Additional file 1: Appendix 1).

We included conditions amenable to primary prevention by the health care system such as infections that are preventable by hygiene measures or by immunisation. Although these interventions have a population-level impact, individual patients receive these services from primary care. Deaths amenable to early detection and intervention include tuberculosis; patients with symptoms of these conditions require rapid access to diagnosis and treatment. Similarly, while not all premature deaths from hypertension, cerebrovascular disease or cancers with a detectable pre-malignant stage are preventable, the amenable mortality rate can be reduced by prompt identification and effective, protocol based intervention. Mortality amenable to improved treatment and medical care comprises those conditions where the likelihood of death without treatment is high and includes diabetes and thyroid disease (where most treatment is in primary care). These are chronic diseases for which a combination of medication, active follow-up and secondary prevention reduces the risk of adverse events. By comparison, conditions amenable to specialist care include cancers without an obvious preventable cause such as cancer of the testis, where treatment in a specialist centre produces high cure rates.

We ran the analyses for all cause, total disease and amenable mortality. We did not categorise separately deaths amenable to health policy, such as those related to substance misuse. We were unable to include deaths due to “accident or misadventure due to healthcare” as these are not classified separately in Finnish routine datasets on causes of death. Such deaths usually represent a small fraction of all amenable mortality [2].

**Income data**

We studied amenable mortality by family net income in adults (25-74 years). Income data from annual tax statistics were linked to individuals by personal identification codes. To avoid indirect identification of rare events, Statistics Finland tabulated annual data by socio-demographic variables. Age was classified into five year age bands and income was adjusted for family size using the OECD equivalence scale and grouped according to quintile limits derived from the population at risk [30]. Those with no recorded income were assigned to the lowest income group. Income was linked to individuals based on income during the previous calendar year for the entire population at risk.

**Statistical methods**

We directly age-standardized mortality rates in 1992-93 and 2002-03 for total and subgroups of amenable mortality using the European standard population. Annual age-standardized mortality rates were calculated by income quintile. We examined trends in amenable mortality by income quintiles using a repeated cross-sectional design, with the count of deaths in cells defined by income quintile, age group and year modelled using Poisson regression and including an interaction between income and year. All models were stratified by sex.

**Trends**

While the main focus was of our work was on relative inequalities, we examined trends over time in the absolute levels of socioeconomic patterning of amenable mortality by reviewing the numbers of deaths, evaluating changes in the age-standardised amenable mortality rate and calculating the reduction in the average amenable mortality rate by income quintile. Average annual changes were obtained from estimates of linear time trends in age-adjusted repeated measures Poisson regression models.

To assess differences in amenable mortality by income quintile we examined data in three four-year periods (1992-1995, 1996-1999 and 2000-2003). Again, we modelled mortality rates using Poisson regression models but with these periods in place of the individual year. Rate ratios for contrasts were used to describe the relative magnitude of amenable mortality in lower income quintiles compared to the highest one in each of the three periods [31]. Further, we determined the annual contribution of mortality amenable to the place of intervention: primary and specialist care, and to the type of intervention: individual preventive services, early detection and intervention, and improved treatment and medical care to differences in total amenable mortality between the highest and lowest income quintiles. To minimise potential misclassification of income or amenability associated with serious underlying disease, we also analysed income differences excluding patients resident in long-term institutions.

Statistical analyses were performed using SAS System for Windows, release 9.1.3. [32].

**Results**

During the study period, the total number of deaths in people aged 25-74 years declined from a two year average of 21609 in 1992-93 to a two year average of 18719
in 2002-03. Total disease mortality (excluding external causes) reduced from 18430 to 15994. The number of deaths per year classified as amenable among men and women aged 25 to 74 years decreased from a two year average of 4072 in 1992-1993 to 3265 in 2002-2003. Table 1 illustrates the reduction in all cause, total disease and amenable mortality.

Amenable mortality decreased more rapidly than all cause and total disease mortality. Among men in 2002-03, amenable mortality accounted for 13% of total mortality and 16% of disease mortality, among women the figures were 26% and 28%. The average annual reduction in amenable mortality (3.6%) was greater than that for all cause (2.8%) and total disease mortality (3.0%) for men. Among women the reduction was more modest. The annual average decline in amenable mortality across the study period was 3.1%, compared with 2.6% for all cause and for total disease mortality. The annual average decline in amenable mortality showed a socioeconomic gradient; in the highest income group this was -5.9% (95% CI -6.7 to -5.8) for men and -4.1% (95% CI -5.1 to -3.1) for women, whereas in the lowest income group the annual average decline was -0.9% (95% CI -2.0 to 0.2) for men and -1.0 (95% CI -2.3 to -0.3) for women.

The largest subgroups of amenable mortality comprised conditions suitable for early detection and intervention (66% of total amenable mortality among men in 1992-93, and 80% among women). Mortality amenable to improved treatment and medical care comprised 33% of amenable deaths among men and 20% among women. By 2002-2003, deaths amenable to improved treatment and medical intervention in primary care comprised 5% of amenable mortality.

The study period was 3.1%, compared with 2.6% for all cause and for total disease mortality. The annual average decline in amenable mortality showed a socioeconomic gradient; in the highest income group this was -5.9% (95% CI -6.7 to -5.8) for men and -4.1% (95% CI -5.1 to -3.1) for women, whereas in the lowest income group the annual average decline was -0.9% (95% CI -2.0 to 0.2) for men and -1.0 (95% CI -2.3 to -0.3) for women.

The largest subgroups of amenable mortality comprised conditions suitable for early detection and intervention (66% of total amenable mortality among men in 1992-93, and 80% among women). Mortality amenable to improved treatment and medical care comprised 33% of amenable deaths among men and 20% among women. By 2002-2003, deaths amenable to improved treatment and medical intervention in primary care comprised 5% of amenable mortality.

### Table 1 Age-standardized amenable mortality rate for 100,000 population aged 25-74, proportion of total amenable mortality (years 1992-93 and 2002-03) and average annual changes (%)

|                     | 1992-93 |          | 2002-03 |          | Average annual change % 95%CI |
|---------------------|---------|----------|---------|----------|-------------------------------|
|                     | avg number of deaths per year | Mortality rate % of total amenable mortality | avg number of deaths per year | Mortality rate Amenable mortality |                                |
| **Men**             |         |          |         |          |                               |
| All cause mortality  | 14038   | 990      | 12512   | 739      | -2.8 (-3.0 - -2.7)            |
| Total disease mortality | 11557 | 828      | 10395   | 611      | -3.0 (-3.1 - -2.8)            |
| Total amenable mortality | 2032 | 144      | 100     | 1678     | 99 100 -3.6 (-4.0 - -3.2)      |
| Primary prevention   | 0       | 0        | 0       | 0        | *                             |
| Early detection and intervention | 1358 | 97       | 1137    | 67       | 67.6 -3.7 (-3.2 - -3.3)       |
| - tuberculosis       | 40      | 3        | 18      | 1        | 1.0 -10.0** (-13.1 - -6.9)    |
| - malignant neoplasm | 273     | 20       | 289     | 17       | 17.2 -1.3 (-2.2 - -0.3)       |
| - hypertension and cerebrovascular disease | 1046 | 75       | 831     | 49       | 49.3 -4.3 (-4.8 - -3.8)       |
| Improved treatment and medical care | 674 | 46       | 541     | 32       | 32.4 -3.3 (-3.9 - -2.6)       |
| - Predominantly primary care | 105 | 6        | 84      | 5        | 5.1 -1.3 (-3.1 - -0.4)        |
| - Predominantly specialist care | 569 | 40       | 457     | 27       | 27.3 -3.6 (-4.3 - -2.9)       |
| Ischaemic heart disease | 4188 | 303      | 2926    | 172      | -5.6 (-5.9 - -5.3)            |
| **Women**            |         |          |         |          |                               |
| All cause mortality  | 7571    | 420      | 6207    | 324      | -2.6 (-2.8 - -2.4)            |
| Total disease mortality | 6873 | 377      | 5599    | 289      | -2.6 (-2.8 - -2.4)            |
| Total amenable mortality | 2040 | 114      | 1587    | 83       | 100 -3.1 (-3.5 - -2.7)        |
| Primary prevention   | 0       | 0        | 0       | 0        | *                             |
| Early detection and intervention | 1653 | 93       | 1320    | 69       | 83.0 -3.0 (-3.5 - -2.7)       |
| - tuberculosis       | 22      | 1        | 0       | 0.5      | 0.5 -6.7** (-10.7 - -2.7)     |
| - malignant neoplasm | 782     | 47       | 756     | 40       | 48.7 -1.0 (-1.6 - -0.4)       |
| - Hypertension and cerebrovascular disease | 849 | 45       | 556     | 28       | 33.8 -5.4 (-6.0 - -4.7)       |
| Improved treatment and medical care | 387 | 21       | 267     | 14       | 17.0 -3.2 (-4.1 - -2.3)       |
| - Predominantly primary care | 49 | 3        | 43      | 3        | 3.1 -1.1 (-3.5 - 1.3)         |
| - Predominantly specialist care | 338 | 18       | 224     | 12       | 13.9 -3.5 (-4.5 - -2.6)       |
| Ischaemic heart disease | 1573 | 80       | 844     | 41       | -6.8 (-7.3 - -6.4)            |

* Due to small numbers RRs were not estimated.

** Due to few deaths in younger age bands 25-44 years old were combined into one age-group for RR estimates.
mortality among men and 3% among women while deaths responsive to intervention in secondary care accounted for 29% of amenable mortality among men and 17% among women.

In 1992-93, the start of our study period, ischaemic heart disease (IHD) comprised 30% of total mortality and 36% of disease mortality among men aged 25-74 years. Among women, IHD mortality accounted for 19% of total mortality and 22% of disease mortality. Between 1992-2003 the annual number of ischaemic heart disease deaths declined from 5761 to 3771, from 192 to 109 per 100,000 among men, and from 51 to 26 per 100,000 in women. The average annual reduction in mortality attributed to ischaemic heart disease was 5.6% in men (95% CI 5.9 to -5.3%) and 6.8% among women (7.3 to -6.4%).

All income groups and both genders experienced an average annual reduction in premature mortality attributable to ischaemic heart disease that was greater than that for amenable mortality excluding IHD. The average annual reduction was -7.9 (95% 8.6 to 7.1) among men and -7.2 (95% CI -9.7 to -4.7) among women in the highest income group compared with -2.3 (95% CI -3.2 to -1.5) among men and -3.8 (95% CI -4.8 to -2.8) among women in the lowest income group.

Tables 2 (men) and 3 (women) present the gradient in risk ratios for amenable mortality by income in the three periods. The annual rate of change appeared fairly linear and while the pattern differed by income group, none of the rules for using this approach were violated. Among men, the gradient in amenable mortality across income groups was similar to that found in all cause and total disease mortality. The gradients increased from the early 1990s to early 2000s. The rate ratios by income in mortality amenable to early detection and intervention were more modest but followed a similar trend, increasing from 2.00 in 1992-3 to 2.66 in 2002-3. Relative income differences were considerably larger for mortality amenable to improved treatment and medical care than those found for all cause (2.53 in 1992-3 to 3.26 in 2002-3) or disease mortality in the lowest income group (1.20 (not significant) in 1992-3 to 2.91 in 2002-2003). The gradient in mortality amenable to improved treatment and medical care also increased over the study period. In 1992-3, the risk ratio for mortality amenable to improved treatment and medical care in primary care was 5.87 and 5.31 for treatment in specialist settings. By 2002-03, the relative mortality risk of men in the lowest income group was 14 times that of the highest income group for mortality amenable to primary care and just less than nine times for mortality amenable to specialist care.

Among women, the income gradient was generally less pronounced than for men although exceptions were seen for mortality amenable to improved treatment and medical care. Here the rate ratio in the lowest income group was 20.54 times that of the highest income group for primary care and 10.36 for specialist care by 2000-2003.

There was no significant gradient for cancer at the start of the study period. The gradient remained modest relative to other conditions but it increased to 1.31 for men and 1.57 for women by 2003. While the mix of cancers was different for men and women, cancer is an important source of amenable mortality for women comprising 40% in 1992, rising to 48% of total amenable mortality by 2003.

The gradient in premature mortality attributed to ischaemic heart disease was similar to that found when all categories of amenable mortality were combined. As was found for amenable mortality, the income gradient for ischaemic heart disease increased significantly, albeit more modestly, over time (p < 0.01).

Figure 1 shows that amenable mortality declined in men and women in all income groups. By 2003 the gender gap had disappeared for those in the highest and second highest income group. Overall amenable mortality in men in the highest income group (50.98 per 100,000) was lower than that for women (53.85 per 100,000). The excess amenable mortality in men persisted for those in the lowest income group; in 2003 the rate in men was 1.44 times that in women. The decline in amenable mortality in men and women in the lowest income group between 1992-2003 was modest, around 11% (from 237.23 per 100,000 in 1992 to 212.96 in 2003), while the rate halved for men in the highest income group (from 103.99 in 1992 50 50.98 in 2003). Reanalysing the data excluding individuals resident in long term institutions decreased income gradients a little, but did not alter the findings.

Discussion
Analysis of comprehensive, individual level data demonstrated that amenable mortality in Finland varied systematically by income group between 1992 and 2003: the lower the income, the higher the risk of amenable mortality. During this period, the absolute and relative gap between the highest and lowest income groups widened with an excess of 28.74 amenable deaths per 100,000 among men in 2003 compared with 1992. Income related differences were particularly high for mortality amenable to improved treatment and medical care in primary healthcare. Towards the end of the study period, the risk ratio for amenable mortality for the lowest income quintile was 14 times that of the highest quintile for men and 21 times that for women. These large risk ratios reflect very few deaths from causes such as asthma, diabetes or epilepsy among the richest quintile.

The socio-economic gradient in amenable mortality increased, with limited reductions in the age-standardized...
Table 2 Socioeconomic gradients in risk ratios for amenable mortality by income and cause of death, men aged 25-74

| Income | Period I: 1992 – 95 | Period II: 1996 – 99 | Period III: 2000 – 03 | Period interactions | p value |
|--------|---------------------|---------------------|---------------------|---------------------|---------|
|        | RR 95% CI           | RR 95% CI           | RR 95% CI           | RR 95% CI          |         |
| All cause mortality                      |                     |                     |                     |         |
| 5      | 1.00 1.00           | 1.00 1.00           | 1.00 1.00           | PI vs PII          | <.001   |
| 4      | 1.35 (1.18 - 1.54)  | 1.39 (1.20 - 1.61)  | 1.41 (1.23 - 1.61)  | PII vs PIII        | <.001   |
| 3      | 1.67 (1.49 - 1.88)  | 1.77 (1.55 - 2.02)  | 1.80 (1.58 - 2.04)  | PI vs PII          | <.001   |
| 2      | 2.15 (1.89 - 2.44)  | 2.41 (2.10 - 2.77)  | 2.60 (2.26 - 3.00)  |                     |         |
| 1      | 2.89 (2.54 - 3.28)  | 3.49 (3.03 - 4.03)  | 4.17 (3.57 - 4.88)  |                     |         |
| Total disease mortality                   |                     |                     |                     |         |
| 5      | 1.00 1.00           | 1.00 1.00           | 1.00 1.00           | PI vs PII          | <.001   |
| 4      | 1.36 (1.19 - 1.57)  | 1.41 (1.22 - 1.64)  | 1.42 (1.24 - 1.63)  | PII vs PIII        | <.001   |
| 3      | 1.67 (1.47 - 1.89)  | 1.77 (1.54 - 2.03)  | 1.81 (1.59 - 2.06)  | PI vs PII          | <.001   |
| 2      | 2.07 (1.81 - 2.38)  | 2.32 (2.01 - 2.769) | 2.53 (2.17 - 2.94)  |                     |         |
| 1      | 2.59 (2.28 - 2.95)  | 3.18 (2.73 - 3.71)  | 3.82 (3.23 - 4.52)  |                     |         |
| Total amenable mortality                  |                     |                     |                     |         |
| 5      | 1.00 1.00           | 1.00 1.00           | 1.00 1.00           | PI vs PII          | <.001   |
| 4      | 1.20 (0.99 - 1.45)  | 1.46 (1.19 - 1.78)  | 1.35 (1.10 - 1.66)  | PII vs PIII        | 0.09    |
| 3      | 1.46 (1.23 - 1.73)  | 1.68 (1.42 - 1.99)  | 1.65 (1.39 - 1.97)  | PI vs PII          | <.001   |
| 2      | 1.90 (1.59 - 2.267) | 2.31 (1.91 - 2.80)  | 2.43 (1.98 - 2.97)  |                     |         |
| 1      | 2.83 (2.40 - 3.33)  | 3.91 (3.27 - 4.68)  | 4.13 (3.37 - 5.06)  |                     |         |
| Early detection and intervention           |                     |                     |                     |         |
| 5      | 1.00 1.00           | 1.00 1.00           | 1.00 1.00           | PI vs PII          | <.001   |
| 4      | 1.11 (0.94 - 1.29)  | 1.37 (1.18 - 1.60)  | 1.28 (1.08 - 1.53)  | PII vs PIII        | 0.49    |
| 3      | 1.31 (1.14 - 1.50)  | 1.53 (1.35 - 1.74)  | 1.47 (1.27 - 1.70)  | PI vs PII          | <.001   |
| 2      | 1.61 (1.40 - 1.85)  | 1.87 (1.61 - 2.19)  | 1.98 (1.66 - 2.35)  |                     |         |
| 1      | 2.00 (1.75 - 2.27)  | 2.67 (2.26 - 3.16)  | 2.66 (2.25 - 3.15)  |                     |         |
| - malignant neoplasm                      |                     |                     |                     |         |
| 5      | 1.00 * 1.00         | 1.00 1.00           | 1.00 1.00           | PI vs PII          | 0.09    |
| 4      | 0.85 (0.66 - 1.08)  | 1.10 (0.94 - 1.28)  | 1.05 (0.85 - 1.31)  | PII vs PIII        | 0.05    |
| 3      | 0.78 (0.63 - 0.97)  | 1.12 (0.97 - 1.29)  | 1.02 (0.85 - 1.21)  | PI vs PII          | 0.46    |
| 2      | 0.98 (0.79 - 1.21)  | 1.18 (1.03 - 1.35)  | 1.21 (1.03 - 1.41)  |                     |         |
| 1      | 0.90 (0.75 - 1.08)  | 1.25 (1.01 - 1.55)  | 1.31 (1.04 - 1.64)  |                     |         |
| - hypertension and cerebrovascular disease|                     |                     |                     |         |
| 5      | 1.00 1.00           | 1.00 1.00           | 1.00 1.00           | PI vs PII          | <.001   |
| 4      | 1.21 (1.03 - 1.43)  | 1.51 (1.27 - 1.79)  | 1.41 (1.13 - 1.76)  | PII vs PIII        | 0.25    |
| 3      | 1.52 (1.32 - 1.75)  | 1.71 (1.49 - 1.97)  | 1.72 (1.43 - 2.05)  | PI vs PII          | <.001   |
| 2      | 1.85 (1.60 - 2.15)  | 2.19 (1.85 - 2.59)  | 2.39 (1.94 - 2.96)  |                     |         |
| 1      | 2.37 (2.06 - 2.72)  | 3.23 (2.72 - 3.84)  | 3.35 (2.75 - 4.07)  |                     |         |
| - Improved treatment and medical care      |                     |                     |                     |         |
| 5      | 1.00 1.00           | 1.00 1.00           | 1.00 1.00           | PI vs PII          | <.001   |
| 4      | 1.46 (1.07 - 1.97)  | 1.69 (1.20 - 2.39)  | 1.57 (1.18 - 2.08)  | PII vs PIII        | 0.03    |
| 3      | 1.87 (1.41 - 2.48)  | 2.09 (1.50 - 2.21)  | 2.25 (1.74 - 2.92)  | PI vs PII          | <.001   |
| 2      | 2.77 (2.06 - 3.71)  | 3.74 (2.75 - 5.09)  | 4.01 (3.06 - 5.26)  |                     |         |
| 1      | 5.47 (4.16 - 7.19)  | 7.93 (5.93 - 10.6)  | 9.43 (7.32 - 12.1)  |                     |         |
death rates among the lowest income group. Widening inequalities in all cause and total disease mortality were more modest. While a detailed analysis of gender differences in amenable mortality is beyond the scope of this paper, amenable mortality rates remained higher in men than women except for the highest income quintile. In addition, the gender gap for amenable mortality was narrower than that for all-cause or total disease mortality and the reduction over time greater [33].

Since the initial studies of amenable mortality, the age limit for amenable death has increased from 65 to 75 years in Western Europe, reflecting increased life expectancy [1]. The fall in premature deaths reflects lower exposure to several risk factors, notably smoking, and more effective medical care [34,35]. Despite the overall decline in amenable mortality rates [36,37] the differential reductions by income groups and the persistent socio-economic gradient illustrates the role of the health system in perpetuating health inequalities [15,38]. Furthermore, the gap between the lowest and second lowest socio-economic group, or between those inside and outside of the workforce [16,39] suggests that health services are not reaching the most disadvantaged. Although the rate is smaller in other countries, the pattern of excess amenable mortality due to chronic conditions such as diabetes is similar to that found among in lower income and minority ethnic groups elsewhere [7,15-18]. More detailed analysis of the relationship between amenable mortality rates and inequities in access, quality and comprehensiveness of care is warranted.

Strengths and limitations
We applied current definitions of amenable mortality [2,7] but our findings are based on comprehensive and reliable individually based linked register data. The level of confirmation of diagnosis at death by autopsy in Finland is high by international comparison [40]. Our data also enabled us to consider the impact of health service changes in the risk of amenable mortality by socio-economic group. In many studies, it is difficult to determine the impact of changes in non-IHD mortality. We analysed IHD deaths separately for three reasons. Firstly, because of the continuing debate about the proportion of mortality from IHD that is amenable to health service intervention. Secondly, the large number of IHD deaths masks the pattern of amenable deaths from other causes, and thirdly, because we analysed individual level, not aggregate data, we could not exclude a proportion of deaths from one condition. We were, however, able to compare trends in IHD deaths with those for amenable mortality as a whole and with other causes of amenable mortality.

Data were incomplete in three areas. As with other register based studies, we had no behavioural data although alcohol and tobacco use clearly contribute to the socio-economic gradient in premature deaths [41,42].

### Table 2 Socioeconomic gradients in risk ratios for amenable mortality by income and cause of death, men aged 25-74 (Continued)

|         | 5   | 4   | 3   | 2   | 1   | PI vs PII |        | PII vs PIII |        | PI vs PIII |        |
|---------|-----|-----|-----|-----|-----|----------|--------|------------|--------|------------|--------|
| Ischaemic heart disease (IHD) |     |     |     |     |     |          |        |            |        |            |        |
|         | 1.00| 1.00| 1.00| 1.00| 1.00| PI vs PII| 0.115*|            |        |            |        |
| 4       | 1.60| 1.19| 1.12| 1.81| 1.52| PII vs PIII| 0.002 |            |        |            |        |
| 3       | 2.04| 1.56| 2.39| 1.46| 1.70| PII vs PIII| 0.001 |            |        |            |        |
| 2       | 2.54| 2.03| 2.10| 2.17| 4.01|            |        |            |        |            |        |
| 1       | 3.51| 2.66| 3.13| 3.44| 6.52|            |        |            |        |            |        |

* Linear income trend not significant at 95% significance level.
### Table 3 Socioeconomic gradients in risk ratios for amenable mortality by income and cause of death, women aged 25-74

| Income | Period I: 1992 - 95 | Period II: 1996 - 99 | Period III: 2000 - 03 | Period interactions | P value |
|--------|--------------------|----------------------|-----------------------|---------------------|--------|
|        | RR                  | 95% CI               | RR                    | 95% CI              | RR     | 95% CI | RR vs PI | PII vs PIII | PI vs PII | PII vs PIII | PI vs PII | PII vs PIII | PI vs PII | PII vs PIII |
| All cause mortality |
| 5      | 1.00                | 1.00                 | 1.00                  |                     | PI vs PII | <.001  |
| 4      | 1.27                | (1.09 - 1.47)        | 1.28                  | (1.10 - 1.48)       | 1.29    | (1.12 - 1.49) | PI vs PII | 0.12 |
| 3      | 1.52                | (1.34 - 1.73)        | 1.55                  | (1.36 - 1.76)       | 1.54    | (1.34 - 1.77) | PI vs PII | <.001 |
| 2      | 1.82                | (1.60 - 2.06)        | 1.98                  | (1.74 - 2.25)       | 2.00    | (1.70 - 2.35) | PI vs PII | <.001 |
| 1      | 2.53                | (2.24 - 2.86)        | 2.98                  | (2.63 - 3.38)       | 3.26    | (2.68 - 3.96) | PI vs PII | <.001 |
| Total disease mortality |
| 5      | 1.00                | 1.00                 | 1.00                  |                     | PI vs PII | <.001  |
| 4      | 1.29                | (1.11 - 1.50)        | 1.29                  | (1.11 - 1.49)       | 1.30    | (1.14 - 1.48) | PI vs PII | 0.24 |
| 3      | 1.53                | (1.34 - 1.74)        | 1.55                  | (1.37 - 1.75)       | 1.53    | (1.34 - 1.75) | PI vs PII | <.001 |
| 2      | 1.80                | (1.58 - 2.05)        | 1.93                  | (1.71 - 2.18)       | 1.95    | (1.67 - 2.27) | PI vs PII | <.001 |
| 1      | 2.47                | (2.18 - 2.81)        | 2.91                  | (2.58 - 3.28)       | 3.12    | (2.58 - 3.76) | PI vs PII | <.001 |
| Total amenable mortality |
| 5      | 1.00                | 1.00                 | 1.00                  |                     | PI vs PII | <.001  |
| 4      | 1.19                | (1.04 - 1.38)        | 1.19                  | (1.04 - 1.38)       | 1.24    | (1.12 - 1.38) | PI vs PII | 0.05 |
| 3      | 1.37                | (1.22 - 1.55)        | 1.43                  | (1.25 - 1.64)       | 1.47    | (1.31 - 1.65) | PI vs PII | <.001 |
| 2      | 1.52                | (1.34 - 1.72)        | 1.62                  | (1.42 - 1.85)       | 1.77    | (1.56 - 2.01) | PI vs PII | <.001 |
| 1      | 2.22                | (1.97 - 2.51)        | 2.57                  | (2.26 - 2.92)       | 2.93    | (2.53 - 3.40) | PI vs PII | <.001 |
| Early detection and intervention |
| 5      | 1.00                | 1.00                 | 1.00                  |                     | PI vs PII | 0.04   |
| 4      | 1.17                | (1.04 - 1.32)        | 1.19                  | (1.06 - 1.35)       | 1.20    | (1.08 - 1.34) | PI vs PII | 0.17 |
| 3      | 1.33                | (1.20 - 1.46)        | 1.39                  | (1.23 - 1.57)       | 1.38    | (1.23 - 1.55) | PI vs PII | <.001 |
| 2      | 1.40                | (1.27 - 1.54)        | 1.49                  | (1.32 - 1.67)       | 1.58    | (1.41 - 1.76) | PI vs PII | <.001 |
| 1      | 1.80                | (1.63 - 1.99)        | 1.99                  | (1.73 - 2.29)       | 2.19    | (1.93 - 2.48) | PI vs PII | <.001 |
| - malignant neoplasm |
| 5      | 1.00                | *                    | 1.00                  |                     | PI vs PII | 0.01   |
| 4      | 1.11                | (0.96 - 1.29)        | 1.19                  | (1.01 - 1.40)       | 1.13    | (0.96 - 1.32) | PI vs PII | <.001 |
| 3      | 1.23                | (1.08 - 1.39)        | 1.40                  | (1.98 - 1.65)       | 1.31    | (1.09 - 1.56) | PI vs PII | <.001 |
| 2      | 1.10                | (0.96 - 1.26)        | 1.28                  | (1.08 - 1.52)       | 1.37    | (1.14 - 1.63) | PI vs PII | <.001 |
| 1      | 1.06                | (0.91 - 1.24)        | 1.29                  | (1.10 - 1.52)       | 1.57    | (1.31 - 1.87) | PI vs PII | <.001 |
| - hypertension and cerebrovascular disease |
| 5      | 1.00                | 1.00                 | 1.00                  |                     | PI vs PII | 0.11   |
| 4      | 1.29                | (1.07 - 1.57)        | 1.23                  | (1.01 - 1.51)       | 1.49    | (1.32 - 1.66) | PI vs PII | 0.21 |
| 3      | 1.55                | (1.31 - 1.82)        | 1.46                  | (1.26 - 1.71)       | 1.74    | (1.57 - 1.94) | PI vs PII | 0.01 |
| 2      | 1.87                | (1.62 - 2.15)        | 1.92                  | (1.69 - 2.18)       | 2.26    | (2.01 - 2.53) | PI vs PII | <.001 |
| 1      | 2.83                | (2.46 - 3.26)        | 3.16                  | (2.72 - 3.66)       | 3.75    | (3.15 - 4.45) | PI vs PII | <.001 |
| Improved treatment and medical care |
| 5      | 1.00                | 1.00                 | 1.00                  |                     | PI vs PII | <.001  |
| 4      | 1.35                | (0.91 - 2.01)        | 1.14                  | (0.73 - 1.77)       | 1.71    | (1.11 - 2.64) | PI vs PII | <.001 |
| 3      | 1.71                | (1.17 - 2.49)        | 1.73                  | (1.15 - 2.61)       | 2.46    | (1.82 - 3.31) | PI vs PII | <.001 |
| 2      | 2.41                | (1.66 - 3.51)        | 2.60                  | (1.76 - 3.83)       | 4.02    | (2.90 - 5.56) | PI vs PII | <.001 |
| 1      | 5.44                | (3.79 - 7.81)        | 6.70                  | (4.55 - 9.88)       | 11.41   | (8.15 - 16.0) | PI vs PII | <.001 |
While the major contribution to reducing tobacco and alcohol related deaths results from policy interventions, smoking cessation [43] and alcohol brief interventions [44] are evidence based primary care treatments that could be used widely among lower income groups in Finland, but are not [45,46]. We also omitted healthcare-associated deaths, as Statistics Finland does not identify these separately in the Causes of Death register.

While we have access to high quality linked data, and we checked the classification of deaths as amenable was appropriate, researchers and policy makers continue to debate the inclusion and exclusion of specific causes, the relationship between evidence for intervention and impact on amenable mortality rates and the boundary between health care and interventions excluded because they are classified as multi-agency or health promotion. All of these concerns are legitimate and are reflected in the final report of the AMIEHS project: Avoidable mortality in the European Union:

Towards better indicators for the effectiveness of health systems: (http://amiehs.lshtm.ac.uk/publications/reports/AMIEHS%20final%20report%20VOL%20I.pdf). We agree with the authors’ caution to avoid direct attribution of a causal relationship between deaths from amenable causes and health system effectiveness but consider that our findings are worrying and worthy of further investigation.

With this dataset, we were also unable to adjust for socio-economic differences in incidence, in the treatability of disease associated with co-morbidity, or delays in seeking medical care. In a universal healthcare system, differential changes in the incidence of treatable disease should not affect the socio-economic gradient in amenable mortality by virtue of being treatable. The extent of the socio-economic gradient in multiple morbidity and its earlier onset in primary care patients living in areas of multiple deprivation has only recently been recognized [47]. It seems plausible that the gradient in amenable mortality reflects the earlier onset and treatability of multiple morbidity in a less responsive health care environment rather than a rise in the incidence of a single specific cause. There is also evidence that lower socio-economic groups have more limited access to treatment known to reduce the risk of early death [48-50] even after adjustment for individual clinical characteristics. However, there is some evidence that attention to populations with higher incidence of disease in designing programmes of care can reduce some aspects of amenable mortality, for example survival after myocardial infarction in South Asian populations in Scotland [51]. Attention to some of the previously identified socioeconomic inequities in access to secondary prevention and treatment of ischaemic heart disease, including revascularization, may explain the more modest increase in gradient in the lowest income group. Similarly, data from the UK indicate that investing in common, chronic conditions associated with amenable mortality can improve outcome [52] although further work is

Table 3 Socioeconomic gradients in risk ratios for amenable mortality by income and cause of death, women aged 25-74 (Continued)

|      | 1      | 1      | 1      | Pt vs PII | 0.41 |
|------|--------|--------|--------|-----------|------|
| 5    | 1.00   | 1.00   | 1.00   | Pt vs PII | 0.41 |
| 4    | 1.20 (0.69 - 2.07) | 1.52 (0.91 - 2.55) | 2.14 (1.08 - 4.23) | Pt vs PII | <.001 |
| 3    | 1.56 (0.89 - 2.73) | 1.99 (1.17 - 3.38) | 3.43 (1.79 - 6.57) | Pt vs PII | <.001 |
| 2    | 2.85 (1.60 - 5.07) | 3.55 (2.18 - 5.80) | 8.42 (4.33 - 16.4) | Pt vs PII | <.001 |
| 1    | 4.55 (2.79 - 7.42) | 6.01 (3.88 - 9.33) | 20.54 (11.4 - 36.8) | Pt vs PII | <.001 |

- predominantly primary care

|      | 1      | 1      | 1      | Pt vs PII | 0.01 |
|------|--------|--------|--------|-----------|------|
| 5    | 1.00   | 1.00   | 1.00   | Pt vs PII | 0.01 |
| 4    | 1.40 (0.90 - 2.18) | 1.06 (0.65 - 1.73) | 1.66 (1.05 - 2.62) | Pt vs PII | 0.01 |
| 3    | 1.74 (1.14 - 2.66) | 1.70 (1.07 - 2.71) | 2.32 (1.70 - 3.17) | Pt vs PII | <.001 |
| 2    | 2.37 (1.55 - 3.62) | 2.51 (1.64 - 3.81) | 3.58 (2.56 - 5.02) | Pt vs PII | <.001 |
| 1    | 5.62 (3.72 - 8.49) | 6.90 (4.50 - 10.6) | 10.36 (7.14 - 15.0) | Pt vs PII | <.001 |

- predominately specialist care

|      | 1      | 1      | 1      | Pt vs PII | 0.01 |
|------|--------|--------|--------|-----------|------|
| 5    | 1.00   | 1.00   | 1.00   | Pt vs PII | 0.01 |
| 4    | 1.40 (1.24-1.58) | 1.49 (1.30-1.70) | 1.57 (1.39-1.78) | Pt vs PII | <.001 |
| 3    | 1.71 (1.54-1.90) | 1.91 (1.67-2.18) | 2.01 (1.77-2.29) | Pt vs PII | <.001 |
| 2    | 2.15 (1.92-2.40) | 2.51 (2.18-2.90) | 2.81 (2.43-3.25) | Pt vs PII | <.001 |
| 1    | 2.51 (2.27-2.80) | 2.97 (2.61-3.39) | 4.01 (3.51-4.59) | Pt vs PII | <.001 |

Ischaemic heart disease

* linear income trend not significant at 95% significance level.

Socioeconomic differences in amenable mortality by income and cause of death. women aged 25-74.
necessary to identify the optimal model of care to address the socioeconomic and age gradient in multiple morbidity.

Since this was a cross-sectional study relating mortality to current income, we were unable to infer the direction of causation. Changes over time in the selection of people with progressive illnesses and multiple morbidity into lower income quintiles could partly explain the gradients found.

Structural change in Finnish health services
Access to diagnosis and ongoing treatment regardless of socioeconomic status or geography characterises universal health systems. However gradients in amenable mortality, particularly for conditions such as hypertension and diabetes persist [7,15,16,38,50]. At the start of the study period, the 2-3 fold socioeconomic gradient in amenable mortality in Finland was similar to that reported by other comprehensive healthcare systems, despite differences in funding, generosity of the social welfare system, and study methodology. By the early 2000s in Finland, educational inequalities in amenable mortality were greater than in other Nordic countries [18] and income related differences were substantially larger.

Inequalities in amenable mortality in Finland widened during a period of structural and economic change. During the study period, municipal primary care received relatively less investment than specialist services. Since the late 1990s most people in stable employment receive primary healthcare from providers with which their employer contracts and GPs no longer provide comprehensive primary care. The expansion in private specialist ambulatory care services also provides more affluent groups with additional opportunities to access care and have the costs partially reimbursed by the social insurance system. The design of these newer services may have changed the help-seeking behaviour of men in higher income groups. Our findings may also reflect the differential impact of comorbidity and complexity of need on the ability of people with lower income to access acute and chronic care in an increasingly complex Finnish healthcare system.

While most chronic conditions occur more frequently among lower income groups, rising co-payments and limited exemptions associated with the health service reforms increase the financial burden of healthcare [53]. In addition, the Finnish health system has been slow to adopt active methods of improving access and treatment [54] for patients with chronic conditions in primary care. Disease registers, call-recall systems, outreach services, continuity of personal care, patient involvement in assessing need and designing services are not widespread in Finland.

Recent analysis of empirical and experimental research has identified some interventions that may reduce socioeconomic inequalities in access to healthcare [55,56]. These include abolition of user fees, strengthening primary care so that it is universally available, expert-based, and actively engages people from disadvantaged groups, particularly those with chronic conditions.

Conclusions
The pattern of amenable deaths in Finland for conditions amenable to treatment and medical care indicates a socio-economic gradient with the position of the lowest income group worsening. These findings are consistent with the expected impact of reducing equity of access to primary medical care and enabling more affluent residents to access additional and specialist services. We therefore urge careful consideration before the implementation of any measures likely to impede equitable access to health care.

Ethics and permissions
The National Research and Development Centre for Welfare and Health Research Ethics Committee approved the research project, data protection measures were agreed with Statistics Finland, and the Finnish data protection ombudsman approved the data linkages.

Additional file

Additional file 1: Table S1. Amenable mortality rates for 25-74 years old by income quintiles in 1992-2003. Annual total amenable mortality per 100,000 - Table of underlying data for Table S1. Appendix 1. Causes
McCallum et al. BMC Health Services Research 2013, 13:3
http://www.biomedcentral.com/1472-6963/13/3

Page 11 of 12

of death considered amenable to health care according to Nolte and McKee (modified).

Competing interests
No competing financial interests.

AKM is the vice-chair of the CHI Advisory Group. This group was established by the Scottish Chief Medical Officer to advise Scottish Directors of Public Health on the appropriate use of the NHS Scotland unique personal identifier for secondary purposes. AKM is also a member of the UK Caldicott Guardians Council and has an interest in the appropriate use of individual level data for secondary purposes, including research. AKM is also asked to advise the Scottish Government Health and Justice Departments from time to time on matters relating to socio-economic inequality and the health of the population: regardless of the findings of this study, the outputs of this research programme would form part of that advice.

AHL is asked to advise the Chief Medical Officer of the Scottish Government from time to time on matters relating to socio-economic inequality and health and how to measure it: regardless of the findings of this study, the outputs of this research programme would form part of that advice.

IK is asked to advise the Finnish Ministry of Health and Social Affairs from time to time on matters relating to socio-economic inequality and health: regardless of the findings of this study, the outputs of this research programme would form part of that advice.

Authors’ contributions
AKM participated in the study design and development, selection of variables, review and interpretation of the results, design and preparation of the manuscript. KM participated in the study design and development, guided the data analysis, interpretation of the results, and preparation of the manuscript. MA participated in the data preparation and analysis and drafting of the methods and findings sections of the manuscript. APL participated in the study design and development, selection of variables, developed the models for analysis, guided the data analysis, participated in the preparation of the manuscript. IK participated in the study design and development, selection of variables, oversaw the data analysis and participated in the interpretation of the results, design and drafting of the manuscript. All authors read and approved the final manuscript.

Acknowledgements
We thank Statistics Finland for provision of anonymised, linked data. The MRC Social and Public Health Sciences Unit is jointly funded by the Academy of Finland (grant 105244 and grant 133793). The Academy of Finland funded the study but had no involvement in its design, data collection, findings or decision to publish.

Author details
1 Directorate of Public Health and Health Policy, NHS Lothian, Waverley Gate, 2-4 Waterloo Place, Edinburgh EH1 3EG, Scotland. 2National Institute for Health and Welfare, (THL), P.O. Box 30, Helsinki FI-00271, Finland. 3MRC/CSO Social and Public Health Sciences Unit, Libby Park, University of Glasgow, Glasgow G12 8RZ, Scotland. 4School of Health Sciences, University of Tampere, Kalevantie 4, 33014, Tampere, Finland.

Received: 11 May 2012 Accepted: 23 November 2012 Published: 3 January 2013

References
1. Nolte E, McKee C. Measuring the health of nations: updating an earlier analysis. Health Aff 2008, 27:58–71.
2. Nolte E, McKee M. Does health care save lives? Avoidable mortality revisited. London: Nuffield Trust; 2004. www.nuffieldtrust.org.uk/ members/download.aspx?f=eocomm/files/21404avoidablemortality2.pdf (accessed 31 Aug 2010).
3. Mackenbach JP. Health care expenditure and mortality from amenable conditions in the European community. Health Policy 1991, 19:245–255.
4. Rustein DD, Berenberg W, Child GG 3rd, Fishman AP, Perin EB. Measuring the quality of medical care. A clinical method. New Engl J Med 1976, 294:582–588.
5. Simonato I, Ballard T, Bellini P, Wilkelmann R. Avoidable mortality in Europe 1955-1994: a plea for prevention. J Epidemiol Community Health 1998, 52:264–250.
6. James PD, Manual DG, Yao Y. Avoidable mortality across Canada from 1975 to 1979. BMC Public Health 2006, 6:137. doi:10.1186/1471-2458-6-137.
7. Tobias M, Jackson G. Avoidable mortality in New Zealand, 1981-97. Aust NZ J Public Health. 2001, 25:12–20.
8. Van Doorslaer E, Masseria C. OECD Health Equity Research Group. Income-related inequality in the use of medical care in 21 OECD countries. In: The OECD Health Project: Towards high-performing health systems. Paris: OECD; 2004:109–166.
9. Keskimäki I. How did Finland’s economic recession in the early 1990s affect socio-economic equity in the use of hospital care? Soc Sci Med 2003, 56:1515–1530.
10. Hetetama T, Keskimäki I, Salomaa V, et al. Socioeconomic inequities in invasive cardiac procedures after first myocardial infarction in Finland in 1995. J Clin Epidemiol 2004, 57:178–185.
11. After DA, Naylor CD, Austin P, et al. Effects of socioeconomic status on access to invasive cardiac procedures and on mortality after acute myocardial infarction. N Engl J Med 1999, 341:1359–1367.
12. Salomaa V, Niemelä M, Miettinen H, et al. Relationship of socioeconomic status to the incidence and prehospital, 28-day, and 1-year mortality rates of acute coronary events in the FINMONICA myocardial infarction register study. Circulation 2000, 101:1913–1918.
13. Forsis E, Keskimäki I, Reunanen A, et al. Widening socioeconomic mortality disparity among diabetic people in Finland. Eur J Public Health 2003, 13:38–43.
14. Manderbacka K, Hetetama T, Keskimäki I, et al. Are there socioeconomic differences in MI event rates and fatality among patients with angina pectoris? J Epidemiol Community Health 2006, 60:442–447.
15. Tobias M, Yeh LC. How much does health care contribute to health inequality in New Zealand? Aust NZ J Public Health 2007, 31:207–210.
16. Wood E, Sallar AM, Schechter MT, et al. Social inequalities in male mortality amenable to medical intervention in British Columbia. Soc Sci Med 1999, 48:751–1758.
17. James P, Wilkins R, Detsky A, et al. Avoidable mortality by neighbourhood income in Canada: 25 years after the establishment of universal health insurance. J Epidemiol Community Health 2007, 61:287–296.
18. Strifu I, Kunst AE, Bopp M, Leinsalu M, Regidor E, Esnaola S, et al. Educational inequalities in avoidable mortality in Europe. J Epidemiol Community Health 2010, 64:913–920. doi:10.1136/jech2008.081737.
19. Hart JT. The inverse care law. Lancet 1971, 2:97–105.
20. Primary Health Care Act: Kansanterveyslaki 2006, 699.
21. Vuorenkoski L, Mladovsky P, Mossialos E: Finland: Health system review. Health Syst Transit 2008, 10:1–168.
22. Kokko S. Integrated primary health care: Finnish solutions and experiences. Int J Integr Care 2009, 9:86.
23. Hakkonen U. Cost containment In Finnish Health Care. In Health Care and Cost Containment in the European Union. Edited by Mossialos E, Le Grand J. Aldershot: Ashgate; 1999:661–699.
24. Manderbacka K, Arffman M, Leyland A, et al. Change and persistence in healthcare inequities: access to elective surgery in Finland in 1992-2003. Scand J Public Health 2009, 37:131–138.
25. Hetetama T, Keskimäki I, Manderbacka K, et al. How did the recent increase in the supply of coronary operations in Finland affect socio-economic and gender equity in their use? J Epidemiol Community Health 2003, 57:178–185.
26. van Doorslaer E, Masseria C, Koolman X. Inequalities in access to medical care by income in developed countries. OMA 2006, 174:177–183.
27. Lahd RA, Pennittia A. The validity of death certificates: routine validation of death certification and its effects on mortality statistics. Forensic Sci Int 2001, 115:15–32.
28. Ministry of Health: Saving Lives: Amenable Mortality in New Zealand, 1996–2006. Wellington: Ministry of Health, 2010.
29. Charlton J, Hartley R, Silver R, et al. Geographical variation in mortality from conditions amenable to medical intervention in England and Wales. Lancet 1983, 321:691–696.
30. OECD. The OECD list of social indicators. Paris: Organisation for Economic Co-operation and Development; 1982.
31. Duncan C, Jones K, Moon G: Health-related behaviour in context: a multilevel modelling approach. Soc Sci Med 1996, 42:817–830.
32. SAS Institute Inc: Cary, NC: SAS Institute Inc; 2007.
33. Martellin T, Makela P, Valtokari T: Contribution of deaths related to alcohol or smoking to the gender difference in life expectancy Finland in the early 1990s. Eur J Public Health 2004, 14:422–427.
34. Bunker J: Medicine matters after all. J Royal Soc Med 1995, 29:105–112.
35. Bunker J, Frazier H, Mosteller F: Improving health: measuring effects of medical care. Milbank Mem Fund Q 1994, 72:225–258.
36. Pokolainen K, Eskola J: Regional and social class variation in the relative risk of death from amenable causes in the city of Helsinki, 1980–1986. Int J Epidemiol 1995, 1:114–118.
37. Korda RJ, Butler JR: Effect of healthcare on mortality: trends in avoidable mortality in Australia and comparisons with Western Europe. Public Health 2005, 120:95–105.
38. Song YM, Byeon JJ: Excess mortality from avoidable and non-avoidable causes in men of low socioeconomic status: a prospective study in Korea. J Epidemiol Community Health 2000, 54:166–172.
39. Westerling R, Gullberg A, Rosen M: Socioeconomic differences in 'avoidable' mortality in Sweden 1986–1990. Int J Epidemiol 1996, 25:560–567.
40. Lunetta P, Lounamaa A, Siivonen S: Surveillance of injury-related deaths: medicolegal autopsy rates and trends in Finland. Inj Prev 2007, 13:282–284.
41. Laaksonen M, Talala K, Martelin T, et al: Health behaviours as explanations for educational level differences in cardiovascular and all-cause mortality: a follow-up of 60,000 men and women over 23 years. Eur J Public Health 2008, 18:38–43.
42. Herttuu K, Makela P, Martikainen P: Changes in alcohol-related mortality and its socioeconomic differences after a large reduction in alcohol prices: a natural experiment based on register data. Am J Epidemiol 2008, 168:1110–1118.
43. Giske K, Kunst AE, Ariza C, et al: Applying an equity lens to tobacco-control policies and their uptake in six Western-European countries. J Public Health Policy 2007, 28:261–280.
44. Kaner EF, Dickinson HO, Beyer FR, Campbell F, Schlesinger C, Heather N, Saunders JB, Bunnand B, Pienaar ED: Effectiveness of brief alcohol interventions in primary care populations. Cochrane Database Syst Rev 2007, doi:10.1002/14651858.CD004148.pub3. Issue 2. Art. No.: CD004148.
45. Helgason AR, Lund KC: General practitioners’ perceived barriers to smoking cessation: results from four Nordic countries. Scand J Public Health 2002, 30:141–147.
46. Aalto M, Pekuri P, Seppa K: Obstacles to carrying out brief intervention for heavy drinkers in primary health care: a focus group study. Drug Alcohol Rev 2003, 22:169–173.
47. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B: Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012, 380:37–43. doi:10.1016/S0140-6736(12)60240-2.
48. Wood E, Montaner JSG, Bangsgberg DR, et al: Expanding access to HIV antiretroviral therapy among marginalized populations in the developed world. AIDS 2003, 17:2419–2427.
49. Woods LM, Rachet B, Coleman MP: Origins of socio-economic inequalities in cancer survival: a review. Ann Oncol 2006, 17S–19.
50. Pieris LS, Carson NJ, Brown K, Ansari Z: Avoidable mortality in Victoria between 1979 and 2001. Aus NZ J Public Health 2007, 31:5–12.
51. Fischbacher CM, Bhopal R, Povey C, Steiner M, Chalmers J, Mueller G, Jamieson J, Knowles D: Record linked retrospective cohort study of 4.6 million people exploring ethnic variations in disease: myocardial infarction in South Asians. BMC Public Health 2007, 7:142. doi:10.1186/1471-2458-7-142.
52. Martin S, Rice N, Smith PC: Does health care spending improve health outcomes? Evidence from English programme budgeting data. J Health Econ 2008, 28:626–842. doi:10.1016/j.jhealeco.2007.12.002.
53. Xu K, Evans DB, Kawabata K, et al: Household catastrophic health expenditure: a multicity analysis. Lancet 2003, 362:111–117.
54. Mantyselka P, Halonen P, Vehvilainen A, et al: Access to and continuity of primary medical care of different providers as perceived by the Finnish population. Scand J Prim Health Care 2007, 25:27–32.
55. World Health Organisation: Commission on Social Determinants of Health Final Report. Closing the gap in a generation. Health equity through action on the social determinants of health. Geneva: World Health Organisation; 2008.
56. Waley J, Lawn J, Tinker A, et al: Primary health care: making Alma-Ata a reality. Lancet 2008, 372:1001–1007.